[PDF][PDF] TNF: a moonlighting protein at the interface between cancer and infection Harald Hundsberger1, Alexander Verin2, Christoph Wiesner1, Maren Pflüger1 …
I Lasters, DN Männel, A Wendel, R Lucas - Frontiers in Bioscience, 2008 - academia.edu
I Lasters, DN Männel, A Wendel, R Lucas
Frontiers in Bioscience, 2008•academia.eduIntroduction 3. Results 3.1. Tumor Necrosis factor: what's in a name? 3.2. Strategies to
increase TNF sensitivity and availability in tumor cells 3.3. Strategies to prevent the systemic
toxicity of TNF, while preserving its anti-cancer effects 3.4. Manipulating intra-hepatic ATP
levels in order to reduce TNF-mediated hepatotoxicity 3.5. TNF receptor 2: an unexpected
player in leukocyte-endothelial interactions and inflammation 3.6. TNF effects on tumor
spreading and endothelial permeability 3.7. The lectin-like domain of TNF: the dark side of …
increase TNF sensitivity and availability in tumor cells 3.3. Strategies to prevent the systemic
toxicity of TNF, while preserving its anti-cancer effects 3.4. Manipulating intra-hepatic ATP
levels in order to reduce TNF-mediated hepatotoxicity 3.5. TNF receptor 2: an unexpected
player in leukocyte-endothelial interactions and inflammation 3.6. TNF effects on tumor
spreading and endothelial permeability 3.7. The lectin-like domain of TNF: the dark side of …
Abstract
Introduction 3. Results 3.1. Tumor Necrosis factor: what’s in a name? 3.2. Strategies to increase TNF sensitivity and availability in tumor cells 3.3. Strategies to prevent the systemic toxicity of TNF, while preserving its anti-cancer effects 3.4. Manipulating intra-hepatic ATP levels in order to reduce TNF-mediated hepatotoxicity 3.5. TNF receptor 2: an unexpected player in leukocyte-endothelial interactions and inflammation 3.6. TNF effects on tumor spreading and endothelial permeability 3.7. The lectin-like domain of TNF: the dark side of the moon. 4. Perspective
academia.edu